Paratek Pharmaceuticals (PRTK) Posts Earnings Results, Misses Expectations By $0.16 EPS

Paratek Pharmaceuticals (NASDAQ:PRTK) released its quarterly earnings results on Tuesday. The specialty pharmaceutical company reported ($1.01) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.16), Fidelity Earnings reports. Paratek Pharmaceuticals had a negative return on equity of 106.39% and a negative net margin of 1,961.41%. The company had revenue of $0.05 million for the quarter, compared to analyst estimates of $5.89 million.

Paratek Pharmaceuticals stock traded up $0.75 during mid-day trading on Wednesday, reaching $7.73. The company’s stock had a trading volume of 1,835,400 shares, compared to its average volume of 649,092. The company has a market cap of $237.65 million, a PE ratio of -2.34 and a beta of 0.74. The company has a debt-to-equity ratio of 2.37, a current ratio of 7.88 and a quick ratio of 7.88. Paratek Pharmaceuticals has a twelve month low of $6.27 and a twelve month high of $22.45.

In other Paratek Pharmaceuticals news, VP Adam Woodrow sold 8,750 shares of Paratek Pharmaceuticals stock in a transaction on Wednesday, October 3rd. The shares were sold at an average price of $9.82, for a total value of $85,925.00. Following the completion of the transaction, the vice president now owns 112,917 shares of the company’s stock, valued at $1,108,844.94. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, COO Evan Loh sold 8,861 shares of Paratek Pharmaceuticals stock in a transaction on Wednesday, October 3rd. The stock was sold at an average price of $9.82, for a total transaction of $87,015.02. Following the completion of the transaction, the chief operating officer now directly owns 235,286 shares of the company’s stock, valued at approximately $2,310,508.52. The disclosure for this sale can be found here. In the last ninety days, insiders sold 58,446 shares of company stock valued at $559,369. 6.20% of the stock is currently owned by corporate insiders.

A number of institutional investors have recently added to or reduced their stakes in the business. JPMorgan Chase & Co. boosted its holdings in Paratek Pharmaceuticals by 6.5% in the third quarter. JPMorgan Chase & Co. now owns 337,110 shares of the specialty pharmaceutical company’s stock worth $3,271,000 after purchasing an additional 20,476 shares during the period. General American Investors Co. Inc. boosted its holdings in Paratek Pharmaceuticals by 12.9% in the third quarter. General American Investors Co. Inc. now owns 436,364 shares of the specialty pharmaceutical company’s stock worth $4,233,000 after purchasing an additional 50,000 shares during the period. Alps Advisors Inc. boosted its holdings in Paratek Pharmaceuticals by 22.5% in the third quarter. Alps Advisors Inc. now owns 56,149 shares of the specialty pharmaceutical company’s stock worth $545,000 after purchasing an additional 10,296 shares during the period. Northern Trust Corp boosted its holdings in Paratek Pharmaceuticals by 13.1% in the second quarter. Northern Trust Corp now owns 408,846 shares of the specialty pharmaceutical company’s stock worth $4,170,000 after purchasing an additional 47,440 shares during the period. Finally, Bank of New York Mellon Corp boosted its holdings in Paratek Pharmaceuticals by 10.2% in the second quarter. Bank of New York Mellon Corp now owns 129,044 shares of the specialty pharmaceutical company’s stock worth $1,316,000 after purchasing an additional 11,980 shares during the period. 77.43% of the stock is owned by hedge funds and other institutional investors.

PRTK has been the subject of a number of recent analyst reports. BidaskClub downgraded shares of Paratek Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Friday, October 12th. ValuEngine raised shares of Paratek Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Tuesday, October 2nd. Guggenheim set a $26.00 price target on shares of Paratek Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, October 3rd. Bank of America initiated coverage on shares of Paratek Pharmaceuticals in a research report on Monday, August 27th. They set a “neutral” rating and a $13.00 price target for the company. Finally, Zacks Investment Research downgraded shares of Paratek Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, August 3rd. Two research analysts have rated the stock with a sell rating, two have given a hold rating and seven have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of $30.29.

TRADEMARK VIOLATION NOTICE: This piece was reported by WKRB News and is the property of of WKRB News. If you are accessing this piece on another site, it was illegally stolen and reposted in violation of U.S. and international copyright law. The legal version of this piece can be read at https://www.wkrb13.com/2018/11/08/paratek-pharmaceuticals-prtk-posts-earnings-results-misses-expectations-by-0-16-eps.html.

About Paratek Pharmaceuticals

Paratek Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics based upon tetracycline chemistry in the United States. Its lead product candidates include omadacycline, an intravenous and oral antibiotic for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections, community-acquired bacterial pneumonia, urinary tract infections, and other community-acquired bacterial infections; and Sarecycline, a tetracycline-derived compound designed for use in the treatment of acne and rosacea.

See Also: Book Value Per Share – BVPS

Earnings History for Paratek Pharmaceuticals (NASDAQ:PRTK)

Receive News & Ratings for Paratek Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply